Drug intelligence / Profile preview

RevaTen

Development stage: Preclinical
Lead developer: BioParadox

Overview

RevaTen is a novel biologic cardiovascular therapy developed by BioParadox, Inc., a regenerative medicine company. It is designed as a point-of-care biologic treatment for cardiovascular disease, with efforts underway to accelerate its commercialization.

Other names: RevaTen

Beyond the preview

Go deeper on RevaTen.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RevaTen.

Explore the full profile